Cargando...
Immunotherapy regimens for metastatic colorectal carcinomas
Metastatic colorectal cancer (mCRC) is a leading cause of cancer-related mortality with a 5-year overall survival rate of 13%. Despite recent advances in cancer immunotherapy, only the minority of CRC patients (<15%) with microsatellite instability can potentially benefit from immune checkpoint i...
Gardado en:
| Publicado en: | Hum Vaccin Immunother |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Taylor & Francis
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5806658/ https://ncbi.nlm.nih.gov/pubmed/29083978 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2017.1397244 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|